Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 676

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 676
---
 This Amendment shall be governed by and construed in accordance with the laws of the State of New York without regard to any conflicts of laws principles thereto that would call for the application of the laws of any other jurisdiction.

6. Counterparts, Facsimile Signatures . This Amendment may be executed in any number of identical counterparts, each of which, for all purposes, is to be deemed an original, and all of which constitute, collectively, one and the same Amendment. Signatures transmitted by electronic means such as email or facsimile shall have the same legal effect as an original signature hereto.

<div align='center'>[Signature page to follow.]

A-87</div>

TABLE OF CONTENTS

IN WITNESS WHEREOF, this Fifth Amendment to Business Combination Agreement has been duly executed and delivered by each of the Parties as of the date first above written.

#### SPAC
Iris Acquisition Corp

By:

/s/ Sumit Mehta

Name:

Sumit Mehta

Title:

Chief Executive Officer

### COMPANY
Liminatus Pharma, LLC

By:

/s/ Chris Kim

Name:

Chris Kim

Title:

CEO, Secretary and Treasurer

### PARENTCO
Iris Parent Holding Corp.

By:

/s/ Chris Kim

Name:

Chris Kim

Title:

CEO, Secretary and Treasurer

<div align='center'>Signature Page to Fifth Amendment to Business Combination

A-88</div>

TABLE OF CONTENTS

### SIXTH AMENDMENT TO BUSINESS COMBINATION AGREEMENT
This Sixth Amendment to Business Combination Agreement (this “

#### Amendment
”) is entered into as of October 23, 2024, by and among Iris Acquisition Corp, a Delaware corporation (the “

#### SPAC
”), Iris Parent Holding Corp., a Delaware corporation (“

#### ParentCo
”), and Liminatus Pharma, LLC, a Delaware limited liability company (the “

#### Company
”). Each of SPAC, ParentCo, and the Company is also referred to herein as a “

#### Party
” and, collectively, the “

#### Parties
”.

### RECITALS
WHEREAS, the Parties, along with Liminatus Pharma Merger Sub, Inc., a Delaware corporation, and SPAC Merger Sub, Inc., a Delaware corporation, entered into that certain Business Combination Agreement, dated November 30, 2022 (the “

#### BCA
”);

WHEREAS, the Parties previously entered into that certain Amendment to Business Combination Agreement, dated June 1,